ABVX Abivax S.A.
USHealthcareAs of 2026-10-08
Why ABVX matters now
Abivax S.A. (ABVX) is a US stock in Healthcare. The latest InvestLog snapshot shows $89.05 with +2.34% on the session and $6.54B in market capitalization; recent performance reads 1-month -12.82% and YTD -26.47%.
The latest financial table shown here is Q4 2025, with revenue of $0.00, net income of $-287.7M, and EPS of $-2.10. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -2.4%.
The latest indexable market news headline is "Cedar Grove Capital Q3 2026 Portfolio Update" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $132.00. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
12.99
P/S
0.00
EV/EBITDA
-25.30
DCF Value
$7.66
FCF Yield
-2.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-165.2%
ROA
-57.5%
ROIC
-45.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-287.7M | $-2.10 |
| FY 2025 | $0.00 | $-336.1M | $-4.65 |
| Q2 2025 | $0.00 | $-48.4M | $-1.59 |
| Q4 2024 | $0.00 | $-52.4M | $-1.50 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$123.43
Target (Median)
$132.00
Target Range
$90.00 - $150.00
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
FR
Exchange
—
Beta
-0.20
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV. Additionally, the company is advancing ABX 196, an immune-boosting candidate, through Phase 1/2 clinical trials targeting hepatocellular cancer. Abivax also conducts research initiatives for conditions like Dengue fever, influenza, and respiratory syncytial virus. The company has secured license agreements with key French scientific bodies, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Founded in 2013, Abivax S.A. maintains its headquarters in Paris, France.